{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:19:11Z","timestamp":1780489151032,"version":"3.54.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/22\/E\/NZ5\/00381"],"award-info":[{"award-number":["2016\/22\/E\/NZ5\/00381"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.biopha.2022.113036","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T19:00:08Z","timestamp":1651086008000},"page":"113036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines"],"prefix":"10.1016","volume":"150","author":[{"given":"Justyna","family":"Borucka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Sterzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Ka\u017amierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u015awierczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nowacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Wojtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Klejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Zabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Januchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113036_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113036_bib2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Bryan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113036_bib3","series-title":"Blaustein\u2019s Pathology of the Female Genital Tract","author":"Kurman","year":"2002"},{"key":"10.1016\/j.biopha.2022.113036_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"Gynecologic Cancer Inter Group (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2022.113036_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx449","article-title":"Harmonising clinical trials within the Gynecologic Cancer Inter Group: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference","volume":"28","author":"Bookman","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib6","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113036_bib7","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib8","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113036_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2022.113036_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.biopha.2022.113036_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.drup.2012.01.006","article-title":"The tumor microenvironment is a dominant force in multidrug resistance","volume":"15","author":"Correia","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.biopha.2022.113036_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fonc.2015.00245","article-title":"The extracellular matrix in epithelial ovarian cancer - a piece of a puzzle","volume":"5","author":"Cho","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib14","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.3390\/ijms19102901","article-title":"The role of matrix gla protein (MGP) expression in paclitaxel and topotecan resistant ovarian cancer cell lines","volume":"19","author":"Sterzy\u0144ska","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113036_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms20010054","article-title":"Mutual expression of ALDH1A1, LOX, and collagens in ovarian cancer cell lines as combined CSCs- and ECM-related models of drug resistance development","volume":"20","author":"Sterzy\u0144ska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113036_bib16","first-page":"20","article-title":"Expression of osteoblast-specific factor 2 (OSF-2, periostin) is associated with drug resistance in ovarian cancer cell lines","volume":"13","author":"Sterzy\u0144ska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113036_bib17","doi-asserted-by":"crossref","first-page":"74466","DOI":"10.18632\/oncotarget.20169","article-title":"The significance of lumican expression in ovarian cancer drug-resistant cell lines","volume":"8","author":"Klejewski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113036_bib18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/biom9120788","article-title":"The impact of integrin-mediated matrix adhesion on cisplatin resistance of W1 ovarian cancer cells","volume":"9","author":"von Rekowski","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113036_bib19","doi-asserted-by":"crossref","first-page":"9240","DOI":"10.3390\/ijms21239240","article-title":"Insight into cisplatin-resistance signaling of W1 ovarian cancer cells emerges mTOR and HSP27 as targets for sensitization strategies","volume":"21","author":"von Rekowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113036_bib20","doi-asserted-by":"crossref","first-page":"49944","DOI":"10.18632\/oncotarget.18278","article-title":"Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines","volume":"8","author":"Januchowski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113036_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2005.03.032","article-title":"The HIN-200 family: more than interferon-inducible genes?","volume":"308","author":"Ludlow","year":"2005","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2022.113036_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/jir.2010.0106","article-title":"The multifaceted interferon-inducible p200 family proteins: from cell biology to human pathology","volume":"31","author":"Gariglio","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.biopha.2022.113036_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2148-12-140","article-title":"The mammalian PYHIN gene family: phylogeny, evolution and expression","volume":"12","author":"Cridland","year":"2012","journal-title":"BMC Evol. Biol."},{"key":"10.1016\/j.biopha.2022.113036_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00218044","article-title":"A novel gene constitutively expressed in human lymphoid cells is inducible with interferon-gamma in myeloid cells","volume":"36","author":"Trapani","year":"1992","journal-title":"Immunogenetics"},{"key":"10.1016\/j.biopha.2022.113036_bib25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1089\/107999002320271413","article-title":"Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells","volume":"22","author":"Gariglio","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.biopha.2022.113036_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00418-002-0485-0","article-title":"Expression of IFI 16 in epithelial cells and lymphoid tissues","volume":"119","author":"Wei","year":"2003","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113036_bib27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cytogfr.2014.06.004","article-title":"IFI16: At the interphase between innate DNA sensing and genome regulation","volume":"25","author":"Jakobsen","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2022.113036_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.arr.2016.04.002","article-title":"IFI16, an amplifier of DNA-damage response: role in cellular senescence and aging-associated inflammatory diseases","volume":"28","author":"Choubey","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.biopha.2022.113036_bib29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2741\/2705","article-title":"Interferon-inducible IFI16 protein in human cancers and autoimmune diseases","volume":"13","author":"Choubey","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.biopha.2022.113036_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molimm.2011.11.004","article-title":"Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear doublestranded DNA: regulation of subcellular localization","volume":"49","author":"Veeranki","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.biopha.2022.113036_bib31","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1073\/pnas.1203447109","article-title":"Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16","volume":"109","author":"Li","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113036_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bbrc.2004.12.056","article-title":"The HIN domain of IFI-200 proteins consistes of two OB-folds","volume":"327","author":"Albrecht","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2022.113036_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.str.2010.12.015","article-title":"Interferon-inducible protein 16: insight into the interaction with tumor suppressor p53","volume":"19","author":"Liao","year":"2011","journal-title":"Structure"},{"key":"10.1016\/j.biopha.2022.113036_bib34","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1038\/sj.onc.1207836","article-title":"Role of IFI 16 in cellular senescence of human fibroblasts","volume":"23","author":"Xin","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.113036_bib35","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1021\/bi981069a","article-title":"Isotypic variants of the interferon inducible transcriptional repressor IFI16 arise through differential mRNA splicing","volume":"37","author":"Johnstone","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2022.113036_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/jir.2009.0096","article-title":"Interferon- inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity","volume":"30","author":"Choubey","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.biopha.2022.113036_bib37","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.febslet.2006.02.015","article-title":"Androgen receptor auto-regulates its expression by a negative feedback loop through up-regulation of IFI16 protein","volume":"580","author":"Alimirah","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2022.113036_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1158\/1541-7786.MCR-06-0269","article-title":"IFI16 in human prostate cancer","volume":"5","author":"Alimirah","year":"2007","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2022.113036_bib39","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1158\/1541-7786.MCR-08-0208","article-title":"Expression of an IFN-inducible cellular senescence gene, IFI16, is up-regulated by p53","volume":"6","author":"Song","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"2003","key":"10.1016\/j.biopha.2022.113036_bib40","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1038\/sj.onc.1206754","article-title":"Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence","volume":"22","author":"Xin","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.113036_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008569","article-title":"Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene","volume":"5","author":"Song","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113036_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jcb.22386","article-title":"Inducible activation of IFI 16 results in suppression of telomerase activity, growth suppression and induction of cellular senescence","volume":"109","author":"Clarke","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.biopha.2022.113036_bib43","first-page":"5","article-title":"The interferon-inducible DNA-sensor protein IFI16: a key player in the antiviral response","volume":"38","author":"Dell\u2019Oste","year":"2015","journal-title":"New Microbiol."},{"key":"10.1016\/j.biopha.2022.113036_bib44","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ni.1932","article-title":"IFI16 is an innate immune sensor for intracellular DNA","volume":"11","author":"Unterholzner","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biopha.2022.113036_bib45","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1074\/jbc.M701846200","article-title":"A novel role of the interferon-inducible protein IFI16 as inducer of proinflammatory molecules in endothelial cells","volume":"282","author":"Caposio","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113036_bib46","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/eji.200939995","article-title":"The interferon-inducible gene IFI16 secretome of endothelial cells drives the early steps of the inflammatory response","volume":"40","author":"Baggetta","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2022.113036_bib47","doi-asserted-by":"crossref","first-page":"20339","DOI":"10.1074\/jbc.M400344200","article-title":"Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation","volume":"279","author":"Fujiuchi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113036_bib48","doi-asserted-by":"crossref","first-page":"40899","DOI":"10.1074\/jbc.M308012200","article-title":"IFI16 as a negative regulator in the regulation of p53 and p21Waf1","volume":"278","author":"Kwak","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113036_bib49","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1074\/jbc.M410542200","article-title":"IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor\/JAK\/STAT pathway in medullary thyroid carcinoma cells","volume":"280","author":"Kim","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113036_bib50","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1038\/sj.onc.1204005","article-title":"Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16","volume":"19","author":"Johnstone","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.113036_bib51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2559.2004.02000.x","article-title":"Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index","volume":"45","author":"Azzimonti","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.biopha.2022.113036_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3727\/096504009789954672","article-title":"Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays","volume":"18","author":"Ju","year":"2009","journal-title":"Oncol. Res."},{"key":"10.1016\/j.biopha.2022.113036_bib53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2016.05.028","article-title":"Characterization of ovarian cancer cell lines as in vivo models for preclinical studies","volume":"142","author":"Hernandez","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13048-016-0278-z","article-title":"Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines","volume":"9","author":"Januchowski","year":"2016","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.biopha.2022.113036_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.561370","article-title":"Adropin stimulates proliferation and inhibits adrenocortical steroidogenesis in the human adrenal carcinoma (HAC15) cell line","volume":"11","author":"Stelcer","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113036_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.18388\/abp.2012_2076","article-title":"Inhibitors of N-glycosylation as a potential tool for analysis of the mechanism of action and cellular localization of glycoprotein P","volume":"59","author":"Wojtowicz","year":"2012","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.biopha.2022.113036_bib58","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.21873\/anticanres.11493","article-title":"New and old genes associated with topotecan resistance development in ovarian cancer cell lines","volume":"37","author":"Klejewski","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2022.113036_bib59","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/molecules22101717","article-title":"New and old genes associated with primary and established responses to cisplatin and topotecan treatment in ovarian cancer cell lines","volume":"22","author":"\u015awierczewska","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.113036_bib60","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/molecules23040891","article-title":"New and old genes associated with primary and established responses to paclitaxel treatment in ovarian cancer cell lines","volume":"23","author":"\u015awierczewska","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2022.113036_bib61","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3390\/ijms20082053","article-title":"PTPRK expression is downregulated in drug resistant ovarian cancer cell lines, and especially in ALDH1A1 positive CSCs-like populations","volume":"20","author":"\u015awierczewska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113036_bib62","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-04-0311","article-title":"Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells","volume":"4","author":"Peters","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113036_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/1535-7163.111.3.2","article-title":"Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts","volume":"3","author":"Bani","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113036_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109552","article-title":"Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity","volume":"69","author":"Krze\u015bniak","year":"2020","journal-title":"Cell Signal."},{"key":"10.1016\/j.biopha.2022.113036_bib65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2022.113036_bib66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1210\/en.2005-0617","article-title":"Horwitz: Estradiol regulates different genes in human breast tumor xenografts compared with identical cells in culture","volume":"147","author":"Harvell","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113036_bib67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2015.08.003","article-title":"Bisphenol A (BPA) stimulates the interferon signaling and activates the inflammasome activity in myeloid cells","volume":"415","author":"Panchanathan","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113036_bib68","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1073\/pnas.0308181101","article-title":"Regulation of ultraviolet light-induced gene expression by gene size","volume":"101","author":"McKay","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113036_bib69","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1158\/1541-7786.MCR-08-0208","article-title":"Expression of an IFN-inducible cellular senescence gene IFI16, is up-regulated by p53","volume":"6","author":"Song","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113036_bib70","first-page":"131","article-title":"The genetics of the E2F family of transcription factors: shared functions and unique roles","volume":"2002","author":"DeGregori","year":"1602","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2022.113036_bib71","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1101\/gad.813200","article-title":"The Rb\/E2F pathway: expanding roles and emerging paradigms","volume":"14","author":"Harbour","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113036_bib72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41698-019-0103-4","article-title":"Interferon-\u03b3 signaling is associated with BRCA1 loss-of function mutations in high grade serous ovarian cancer","volume":"3","author":"Cardenas","year":"2019","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2022.113036_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109790","article-title":"IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway","volume":"123","author":"Cai","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2022.113036_bib74","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0002-9440(10)63178-1","article-title":"Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas","volume":"164","author":"Sato","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.113036_bib75","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2605.2007.00758.x","article-title":"Improved gene expression signature of testicular carcinoma in situ","volume":"30","author":"Almstrup","year":"2007","journal-title":"Int. J. Androl."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:55:42Z","timestamp":1780487742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222004255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":75,"alternative-id":["S0753332222004255"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113036","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significance of interferon gamma inducible protein 16 (IFI16) expression in drug resistant ovarian cancer cell lines","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113036"}}